European principles of care for women and girls with inherited bleeding disorders
van Galen, Karin; Lavin, Michelle; Skouw-Rasmussen, Naja; Fischer, Kathelijn; Noone, Declan; Pollard, Debra; Mauser-Bunschoten, Eveline; Khair, Kate; Gomez, Keith; van Loon, Ellen; Bagot, Catherine N; Elfvinge, Petra; d'Oiron, Roseline; Abdul-Kadir, Rezan; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)
(2021) Haemophilia, volume 27, issue 5, pp. 837 - 847
(Article)
Abstract
INTRODUCTION: Despite increasing awareness of issues faced by women and girls with inherited BDs (WGBD), standards of care are lacking, with disparities in diagnosis and treatment for WGBD across Europe. We aimed to develop practical principles of care (PoC) to promote standardization of care for WGBD within European Haemophilia Treatment
... read more
and Comprehensive Care Centres (HTC/CCCs). METHODS: The co-creation process, supported by the European Association for Haemophilia and Allied Disorders, consisted of four multidisciplinary meetings with health care providers (HCPs) experienced in WGBD care, and European Haemophilia Consortium representatives, combined with broad patient and HCP consultations in the European haemophilia community. Relevant medical societies outside Europe were contacted for confirmation. RESULTS: We developed ten PoC for WGBD, stressing the importance and benefits of a centralized, multidisciplinary, comprehensive, family-centred approach to support and manage WGBD during all life stages. These PoC emphasise the right to equitable access and quality of care for all people with BDs, irrespective of gender. Multiple medical societies outside Europe also confirmed their support for endorsement. CONCLUSIONS: Ten PoC for WGBD evolved from an iterative process among stakeholders, supported by relevant medical societies worldwide. These PoC can serve as a benchmark for diagnosis and comprehensive multidisciplinary management of WGBD, and improve awareness of their unique challenges. They offer a framework to guide HTC/CCCs in providing equitable care for all WGBD, both in their own services and in other healthcare settings. Implementation of these principles aims to positively impact the health, wellbeing and quality of life for WGBD.
show less
Download/Full Text
Keywords: bleeding disorder, heavy menstrual bleeding, postpartum haemorrhage and reproduction, pregnancy, principles of care, women, Hematology, Genetics(clinical)
ISSN: 1351-8216
Publisher: Wiley-Blackwell
Note: Funding Information: This project was fully supported by the European Association for Haemophilia and Allied Disorders without commercial funding. In addition would like to thank Dawn Rotellini (World Federation of Hemophilia and National Haemophilia Foundation), Maha Othman (International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on Women's Health Issues in Thrombosis and Haemostasis chair), Kerry Funkhouser (Foundation for Women and Girls with Blood Disorders) and Amanda Bok (European Haemophilia Consortium CEO) for their help and support. Finally we would like to express our gratefulness all patients and HCPs who provided input or feedback throughout the process. Funding Information: Dr. van Galen has received unrestricted research grants from CSL Behring and Bayer and Octapharma and speakers fee from Takeda, CSL Behring and Bayer. Dr. Lavin received consultancy fees for Takeda and an advisory board for Tremeau Pharmaceuticals, and served as a consultant for Sobi. D. Pollard received speakers fee from CSL, Roche‐Chugai, NovoNordisk, Sobi, Takeda and advisor/consultancy fees from BioMarin, CSL, Takeda, Roche, NovoNordisk. Dr. d'Oiron has served as a consultant for Baxalta/Shire, Bayer, Biomarin, CSL Behring, LFB, NovoNordisk, Octapharma, Pfizer, Roche and Sobi, Spark and was invited speaker for Baxalta/Shire, Bayer, CSL Behring, LFB, NovoNordisk, Octapharma, Pfizer, Roche and Sobi. Dr Khair has received unrestricted research grants from CSL Behring, Pfizer, Roche, SOBI, uniQure and consultancy/speaker fees from Bayer, Biomarin, CSL Behring, HCD Economics, Novo Nordisk, Pfizer Roche, SOBI and Takeda. Dr. Fischer has received speaker's fees from Bayer, Baxter/Shire, SOBI/Biogen, CSL Behring, NovoNordisk; performed consultancy for Bayer, Biogen, CSL‐Behring, Freeline, NovoNordisk, Roche and SOBI; and has received research support from Bayer, Baxter/Shire, Novo Nordisk, Pfizer and Biogen. Dr Gomez has received unrestricted research grants from Bayer and Pfizer and, consultancy and speaker fees from Bayer, Biomarin, BPL, CSL Behring, Novo Nordisk, Pfizer, Roche, Sanofi, Sobi and Takeda. Prof Abdul‐Kadir received lecture fees/ educational grants from Pfizer, NovoNordisk, Takeda and ViforParma. Publisher Copyright: © 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.
(Peer reviewed)